Abhishek Pathak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Abhishek Pathak has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anvesh Rathore
Army Hospital, Research and Referral, New Delhi, India
3 shared publicationsAlpana Gupta
Transfusion Centre, West Bengal, Kolkata, India
2 shared publicationsRicha Ranjan
Command Hospital, Kolkata, West Bengal, India
2 shared publications- Amol Patel
Indian Naval Hospital Ship Asvini (INHS Asvini), Mumbai, India
1 shared publication Amul Kapoor
1 shared publication- Arashdeep Singh
Department of Medicine, INHS Asvini, Mumbai, India
1 shared publication
Latest Publications
- Open Access
- 25 July 2024
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 3 (1) , 1-2
Biohacking for Longevity: Implications for Cancer Research and Treatment
- 25 July 2024
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 3 (1) , 1-2
Open AccessBiohacking for Longevity: Implications for Cancer Research and Treatment
- Open Access
- 28 December 2023
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 2 (2) , 33-34
The Crucial Role of Proteomics in Early Cancer Detection
- 28 December 2023
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 2 (2) , 33-34
Open AccessThe Crucial Role of Proteomics in Early Cancer Detection
- Open Access
- 1 July 2023
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 12 (03) , 238-244
Phase 1/2 Study of the Timing and Efficacy of 3 mg Peg-GCSF in Neo/Adjuvant Dose Dense Breast Cancer Treatment Protocols
Background Peg-GCSF has similar efficacy at a dose of 60 µg/kg and 100 µg/kg. The conventional 6 mg SC dose was based on the maximum tolerable dose. In Japan, 3.6 mg dose was approved on the basis of dose finding studies. Peg-GCSF is an integral part of dose-dense chemotherapy protocols. Dose finding and scheduling study of peg-GCSF have not been conducted in Indian patients. Materials and Methods We conducted two-center phase 1/2 clinical study addressing the timing and efficacy of peg-GCSF in Indian breast cancer patients (CTRI no: 2021/07/034751). Three groups of timing administration were studied, namely 1, 6, and 24 hours post chemotherapy. The phase 2 part was the expansion of the best timing group. The primary objective was dose density, which was defined as receiving chemotherapy on < 3 days of scheduled date. Adriamycin/epirubicin cyclophosphamide (AC/EC) was administered q2 weeks. The total leucocyte (TLC) and absolute neutrophil (ANC) kinetics were studied. Other outcomes were incidence of grade 4 neutropenia, febrile neutropenia (FN), and requirement of additional doses of G-CSF. Bone pain, fever, and myalgia were studied for adverse effects. Results From November 20 to December 21, 36 patients were enrolled. Patient characteristics are depicted in Table 1. Initially, three patients received the peg-GCSF in each timing group. One patient in each 1-hour and 6 hours needed G-CSF support for maintaining the dose density. The 24-hour group was carried to phase 2 part. Dose density was maintained in 97% of patients. None of the patient in 24-hour group had FN. Also, 4/30 patients had grade 4 neutropenia and required an additional dose of GCSF. Grade 3 or 4 bone pain was not noticed by any of the patients. During the first cycle, the mean ANC (cells/μL) was 5284, 20704, 3010, 6954 on D0, D + 3, D + 7, and D + 13, respectively (Fig. 1A-TLC and 1B-ANC). The mean ANC (cells/μL) rise on D + 3 in cycles 1, 2, 3, 4 was 23810, 29209, 32428,22455, respectively. Conclusion Dose density of AC/EC breast cancer protocol is maintained with peg-GCSF 3 mg. Post chemotherapy 24-hour timing of peg-GCSF administration remains as the standard. A phase 3 trial of 6 mg versus 3 mg is warranted.
- 1 July 2023
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 12 (03) , 238-244
Open AccessPhase 1/2 Study of the Timing and Efficacy of 3 mg Peg-GCSF in Neo/Adjuvant Dose Dense Breast Cancer Treatment Protocols
Background Peg-GCSF has similar efficacy at a dose of 60 µg/kg and 100 µg/kg. The conventional 6 mg SC dose was based on the maximum tolerable dose. In Japan, 3.6 mg dose was approved on the basis of dose finding studies. Peg-GCSF is an integral part of dose-dense chemotherapy protocols. Dose finding and scheduling study of peg-GCSF have not been conducted in Indian patients. Materials and Methods We conducted two-center phase 1/2 clinical study addressing the timing and efficacy of peg-GCSF in Indian breast cancer patients (CTRI no: 2021/07/034751). Three groups of timing administration were studied, namely 1, 6, and 24 hours post chemotherapy. The phase 2 part was the expansion of the best timing group. The primary objective was dose density, which was defined as receiving chemotherapy on < 3 days of scheduled date. Adriamycin/epirubicin cyclophosphamide (AC/EC) was administered q2 weeks. The total leucocyte (TLC) and absolute neutrophil (ANC) kinetics were studied. Other outcomes were incidence of grade 4 neutropenia, febrile neutropenia (FN), and requirement of additional doses of G-CSF. Bone pain, fever, and myalgia were studied for adverse effects. Results From November 20 to December 21, 36 patients were enrolled. Patient characteristics are depicted in Table 1. Initially, three patients received the peg-GCSF in each timing group. One patient in each 1-hour and 6 hours needed G-CSF support for maintaining the dose density. The 24-hour group was carried to phase 2 part. Dose density was maintained in 97% of patients. None of the patient in 24-hour group had FN. Also, 4/30 patients had grade 4 neutropenia and required an additional dose of GCSF. Grade 3 or 4 bone pain was not noticed by any of the patients. During the first cycle, the mean ANC (cells/μL) was 5284, 20704, 3010, 6954 on D0, D + 3, D + 7, and D + 13, respectively (Fig. 1A-TLC and 1B-ANC). The mean ANC (cells/μL) rise on D + 3 in cycles 1, 2, 3, 4 was 23810, 29209, 32428,22455, respectively. Conclusion Dose density of AC/EC breast cancer protocol is maintained with peg-GCSF 3 mg. Post chemotherapy 24-hour timing of peg-GCSF administration remains as the standard. A phase 3 trial of 6 mg versus 3 mg is warranted.
- Open Access
- 4 May 2023
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 2 (1) , 1-2
Technology in Oncology
- 4 May 2023
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 2 (1) , 1-2
Open AccessTechnology in Oncology
- Open Access
- 21 November 2022
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 1 (2) , 31-32
Artificial Intelligence in Oncology
- 21 November 2022
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 1 (2) , 31-32
Open AccessArtificial Intelligence in Oncology
- Open Access
- 23 March 2022
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 1 (1) , 2-7
Next-generation Sequencing: For the Present Generation Oncologist
Previously, doctors had to treat this deadly disease based on immunohistochemistry, polymerase chain reaction and fluorescence in situ hybridisation-based diagnostics tests information which used to provide limited information. There was always a requirement of a single test/assay which could give all these information in a single assay and without much loss of precious sample. Comprehensive next-generation sequencing (NGS)-based assays are gaining much importance in treatment decision among clinicians. These present technologies using DNA, RNA, and methylation sequencing have brought a lot of changes in cancer therapeutics. Oncogenic drivers are genomic alteration lead to malignant transformation and progression of cancer. The interpretation of the results of NGS is also very challenging as the results obtained are ‘variants’ are of unknown prognostic significance. Apart from these, NGS helps us in documenting various other genomic signatures such as tumour mutation burden and microsatellite instability. There are now multiple gene panels that are recommended by major international societies such as NCCN, for the treatment of various malignancies. In fact, NGS forms the most important pillar of precision oncology and has brought a paradigm shift in the way major cancers are treated. It is still an evolving field and many times the interpretation of the results of NGS reports is very difficult. NGS-based precision medicine treatment offers true value addition in clinical practice has a positive impact on patient lives in cases of refractory cancer, the role of NGS is the only source of light that helps us in navigating amidst the darkness and hopelessness of a refractory malignancy. In fact, presently not only in refractory malignancies but the role of NGS has come in the management of cancer patients in the first line as it gives us a more comprehensive understanding of the disease. This review article has been written with an idea to make a general practitioner aware of this novel technique, the advantages as well as the pitfalls.
- 23 March 2022
- Published by Scientific Scholar in Indian Cancer Awareness Journal
- Vol. 1 (1) , 2-7
Open AccessNext-generation Sequencing: For the Present Generation Oncologist
Previously, doctors had to treat this deadly disease based on immunohistochemistry, polymerase chain reaction and fluorescence in situ hybridisation-based diagnostics tests information which used to provide limited information. There was always a requirement of a single test/assay which could give all these information in a single assay and without much loss of precious sample. Comprehensive next-generation sequencing (NGS)-based assays are gaining much importance in treatment decision among clinicians. These present technologies using DNA, RNA, and methylation sequencing have brought a lot of changes in cancer therapeutics. Oncogenic drivers are genomic alteration lead to malignant transformation and progression of cancer. The interpretation of the results of NGS is also very challenging as the results obtained are ‘variants’ are of unknown prognostic significance. Apart from these, NGS helps us in documenting various other genomic signatures such as tumour mutation burden and microsatellite instability. There are now multiple gene panels that are recommended by major international societies such as NCCN, for the treatment of various malignancies. In fact, NGS forms the most important pillar of precision oncology and has brought a paradigm shift in the way major cancers are treated. It is still an evolving field and many times the interpretation of the results of NGS reports is very difficult. NGS-based precision medicine treatment offers true value addition in clinical practice has a positive impact on patient lives in cases of refractory cancer, the role of NGS is the only source of light that helps us in navigating amidst the darkness and hopelessness of a refractory malignancy. In fact, presently not only in refractory malignancies but the role of NGS has come in the management of cancer patients in the first line as it gives us a more comprehensive understanding of the disease. This review article has been written with an idea to make a general practitioner aware of this novel technique, the advantages as well as the pitfalls.
- Open Access
- 22 May 2020
- Published by Medip Academy in International Journal of Advances in Medicine
- Vol. 7 (6) , 1035-1039
Chemotherapy in COVID-19 pandemic: to give or not to give?
COVID-19 is a new pathogen for humans, not much is known how it affects cancer patients, but definitely there is high risk for cancer patients contracting this disease. So to find a solution to this very challenging situation the oncologists need to formulate certain guiding principles for cancer treatment in this pandemic era. Authors have divided this cancer patients into four categories depending upon the urgency of giving chemotherapy. The lowest priority being Priority A where delaying chemotherapy till this pandemic gets over will not harm the patients much and the highest priority being given to Priority D where authors do not want even a delay of days/ week. It is Priority B and C where the decision needs to made by the clinicians. However, in case authors decide to give chemotherapy in present setting there are certain changes that needs to be made both on patient as well as the hospital end. Like higher degree of awareness among patients, rational usage of resources of the hospital etc. It is indeed a very difficult time for cancer patients who are trying to cope up with malignancy and for most of them; the coronavirus is an extra concern and worry. Till the time authors learn how best treat and care to this patients during this pandemic era do what you can do to keep you and your family stay safe and Healthy.
- 22 May 2020
- Published by Medip Academy in International Journal of Advances in Medicine
- Vol. 7 (6) , 1035-1039
Open AccessChemotherapy in COVID-19 pandemic: to give or not to give?
COVID-19 is a new pathogen for humans, not much is known how it affects cancer patients, but definitely there is high risk for cancer patients contracting this disease. So to find a solution to this very challenging situation the oncologists need to formulate certain guiding principles for cancer treatment in this pandemic era. Authors have divided this cancer patients into four categories depending upon the urgency of giving chemotherapy. The lowest priority being Priority A where delaying chemotherapy till this pandemic gets over will not harm the patients much and the highest priority being given to Priority D where authors do not want even a delay of days/ week. It is Priority B and C where the decision needs to made by the clinicians. However, in case authors decide to give chemotherapy in present setting there are certain changes that needs to be made both on patient as well as the hospital end. Like higher degree of awareness among patients, rational usage of resources of the hospital etc. It is indeed a very difficult time for cancer patients who are trying to cope up with malignancy and for most of them; the coronavirus is an extra concern and worry. Till the time authors learn how best treat and care to this patients during this pandemic era do what you can do to keep you and your family stay safe and Healthy.
- Open Access
- 15 June 2016
- Published by OAE Publishing Inc. in Journal of Cancer Metastasis and Treatment
- Vol. 2 (6) , 214
Changing paradigm in treatment of lung cancer
- 15 June 2016
- Published by OAE Publishing Inc. in Journal of Cancer Metastasis and Treatment
- Vol. 2 (6) , 214
Open AccessChanging paradigm in treatment of lung cancer